Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a
biotechnology company and drug-delivery platform innovator, is increasing the
reach of its revolutionary DehydraTECH(TM) technology that enables the rapid
onset of ingested cannabis. An article discussing the company reads,
“DehydraTECH is a drug-delivery technology that gets ingested active
pharmaceutical ingredient (API) molecules to the bloodstream faster than other
methods. Under a new agreement announced July 24, the company will expand
DehydraTECH’s reach by allowing Hill Street Beverage Company Inc. (TSX.V:
BEER), a manufacturer of alcohol-free and cannabis-infused beer, wine and
adult-format beverages, to produce commercial products in partnership with
Lexaria under a new brand that is yet to be announced (http://ibn.fm/BTodZ).”
To view the full article, visit http://ibn.fm/Nxsx8
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the United States and in Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
